# Notes for microbiota research

Put daily work records on microbiota into this repository 

## Review

* [A practical guide to amplicon and metagenomic analysis of microbiome data](https://link.springer.com/article/10.1007/s13238-020-00724-8)
* [Current challenges and best-practice protocols for microbiome analysis](https://academic.oup.com/bib/article/22/1/178/5678919?login=false)
* [Shotgun metagenomics, from sampling to analysis](https://www.nature.com/articles/nbt.3935)
* [Targeting the gut and tumor microbiota in cancer](https://www.nature.com/articles/s41591-022-01779-2)
* [Microbiota in health and diseases](https://www.nature.com/articles/s41392-022-00974-4)
* [The gut microbiotaâ€“brain axis in behaviour and brain disorders](https://www.nature.com/articles/s41579-020-00460-0)
* [Gut microbiota in human metabolic health and disease](https://www.nature.com/articles/s41579-020-0433-9)
* [Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders](https://www.nature.com/articles/s41575-020-0269-9) 



## Book

* [Statistical Analysis of Microbiome Data with R](https://link.springer.com/book/10.1007/978-981-13-1534-3)



## Paper



### Longitudinal study

* [Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults - ScienceDirect](https://www.sciencedirect.com/science/article/pii/S2211124722004016#:~:text=In%20conclusion%2C%20our%20findings%20indicate,in%20AR%20in%20healthy%20microbiomes.)


### NAFLD: non-alcoholic fatty liver disease

* [Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders](https://www.nature.com/articles/s41575-020-0269-9)
* [Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus](https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02526-w)
* [Multiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis](https://onlinelibrary.wiley.com/doi/10.1002/advs.202104373)
